A cyclotron named ARRONAX is being built in Nantes (France). It is mainly devoted to radiochemistry and nuclear medicine research and will be operational the last quarter of 2008. This machine will accelerate both protons and α-particles at high energy (up to 70 MeV) and high intensity (2 simultaneous proton beams with intensity up to 350 µA). In nuclear medicine, these characteristics will allow the cyclotron to produce a large variety of radionuclides on a regular schedule and in sufficient amount to perform clinical trials. A priority list of 12 radioisotopes, which contains isotopes for therapeutic use as well as for PET imaging, has been established by an international scientific committee. In radiochemistry, a vertical pulsed α-beam will allow fundamental studies of radiolysis in aqueous media, which is of great interest for radiobiology and for nuclear waste management.
Introduction
During the past decade, a technological revolution has deeply changed the role of radionuclides in medicine especially in oncology.
PET/CT technology with 18 F-FluoroDeoxyGlucose (FDG) which became clinically available less than 10 years ago, is now accepted as the gold standard in oncology imaging [1] . Moreover some other fluorinated radiopharmaceuticals are currently evaluated [2] and some of them could be approved for a clinical routine use in the coming years.
Radionuclide therapy has been rapidly extended, for the last 10 years, to a large panel of malignant tumors due to the availability of new carriers, including antibodies and peptides, new targeting methods and new radionuclides.
FDG is taken up by any lesion that needs a source of energy for its own metabolism, including inflammatory processes. Such non specific uptake results in a limited diagnostic specificity of FDG-PET. In the future, the use of carriers that are specific for a variety of tumors will allow for specifically targeting cancer cells. This could greatly improve the diagnostic specificity of PET. This new approach, termed immuno-PET, is being evaluated in preclinical studies using different forms of several antibodies. The first results confirmed a higher specificity of immuno-PET as compared to FDG-PET [3, 4] . However, due to its (too) short physical half-life, fluorine-18 is not appropriate for these carriers that are generally large biological molecules with relatively long (some days) kinetics in the body. Consequently there is a need for innovative positron-emitting radionuclides with half-lives longer than 10 hours.
The future of radionuclide therapy will require increasing injected activity to deliver sufficient irradiation dose to kill radio-resistant solid tumor cells while limiting irradiation of vital organs including liver, lung and kidney. It will be necessary to evaluate, as accurately as possible, the doses absorbed by these organs by a pre-therapeutic dosimetric study, using PET to take advantage of its quantification ability which is superior to that of SPECT (single photon emission tomography). Since most therapeutic radionuclides do not emit positrons, it is interesting to use positron emitters of the same element. They will follow the same metabolic pathways and will allow obtaining the radionuclide biodistribution. Couples of β +/β− isotopes of the same element must be available for these studies such as for example 124 I/ 131 I [5] . Finally, another promising approach will be using alpha particle-emitting radionuclides to take advantage of the high LET (linear energy transfer) of alpha particles as compared with that of β-particles [6] .
So, in this context of consequent need for innovative radionuclides, a cyclotron with proton and alpha beams is being built in Nantes, France.
After a description of the accelerator capabilities, we will present the associated facility and the expected list of produced radionuclides.
ARRONAX

ARRONAX (Accelerator for Research in Radiochemistry and
Oncology in Nantes Atlantique) is a high energy (70 MeV) and high intensity (750 µA proton) cyclotron that will produce a large variety of radionuclides on a regular schedule and in sufficient amount to perform clinical trials. It will also offer the possibility to perform experiments in order to better understand the effect of radiolysis which is always present when dealing with radionuclides in solution as well as radiobiological studies.
ARRONAX characteristics
ARRONAX is being build by IBA. It will turn into operation in the last quarter of 2008 in Nantes (France).
This cyclotron will accelerate both positive ions (HH+, He++) and negative ions (H-, D-) up to 70 MeV. It is designed to deliver up to 750 µA of protons and 35 µA of α-particles.
• Negative ions will be extracted using a stripper foil. This technique allows extracting the beam within a large range of incident energy. It has been adapted to deliver two ©2008 CEA, published by EDP Sciences
Article available at http://nd2007.edpsciences.org or http://dx.doi.org/10.1051/ndata:07340 beams at the same time. These beams may have different energies and intensities (up to 350 µA for protons).
• Positive ions will be extracted using an electromagnetic septum. In this case, beams are extracted at a fixed energy (70 MeV for α-particles) and only on one beam output (right side of fig.1 ).
The capabilities of the ARRONAX cyclotron are summarized in the table 1.
The surrounding facility
The cyclotron will deliver beams in 6 experimental vaults named AX, A1, A2, P1, P2, P3 (see fig. 1 ). Due to the extraction method which is different for negative and positive ions, protons and deuterons will be available in every experimental vault whereas α-particles will be available only in vaults A1, A2 and AX. Halls A1, A2, P2 and P3 will be devoted to radionuclide production and will be equipped with an appropriate target system. A rabbit system connected between these vaults and hot cells will limit worker exposition to radiation. These four dedicated vaults will allow flexibility and, together with the high intensity, will ensure availability of radionuclide on a regular schedule.
Vault P1 will be used to perform R&D on highly intense beam. Indeed, if one wants to use the proton beam delivered by ARRONAX at full intensity and full energy, it will have to deal with 25 kW on the target. This remains a challenge and works are starting on that subject.
Vault AX, which is the largest, will be devoted to experiments on radiolysis, radiobiology, physics and for highgrade student training. Three beam lines are available in this vault. The α-beam can be pulsed. Pulse characteristics are the following: a width equal to 3.3 ns, a variable delay between consecutive (from 1ms up to a few seconds), each pulse can contains up to 7 × 10 6 alphas. In addition for radiolysis and radiobiology experiments a vertical beam is available on one of the lines.
Finally, several laboratories (radiochemistry, biochemistry, cells, radio-labeling, chemical analysis, nuclear metrology. . . ) are available.
The scientific program
A large part of the ARRONAX beam time will be devoted to the production of radionuclides mainly for medical application. However, taking advantage of the vertical pulsed α-beam in vault AX, a non negligible beam time will be allowed to radiolysis experiments and radiobiological studies. Fundamental studies of radiolysis in aqueous media are of great interest for radiobiology as well as for nuclear waste management.
In the following section, we will focus on the isotope production. In order to define the most interesting radionuclides to be produced, a priority list has been established by the international scientific committee that has supervised the project since the beginning. This list contains radionuclides for both PET imaging and therapy.
Radionuclides for PET imaging
As presented in the introduction, positron-emitting radionuclides, which are not yet or not readily available, are requested for pre-clinical and clinical applications in oncology as well as for other medical specialties.
Taking advantages of the construction of ARRONAX, we have reinvestigated the periodic table of elements in order to find β + emitters with longer half lives than 18 F and physical properties adapted to PET imaging. We have also take into account the interest of the scientific community by reviewing the existing literature. Starting from over 500 isotopes, we ended up with 10 radionuclides. They have been separated into two groups based on their interest.
Great interest at short term
The isotopes for pre-therapeutic use and those available through generators appear among this group. 124 I, 64 Cu, 86 Y can be used in pre-therapeutic PET dosimetry for an evaluation of tumor and normal organs (liver, kidney, and lung) doses before injection of their β − emitting counterparts ( 131 I, 67 Cu, 90 Y). It should be noted that 86 Y emits non negligible percentages of high energy gamma rays resulting in a relatively high exposure rate and thus requiring some particular radiation safety constraints. 82 Rb is an analog of potassium used in cardiology in the United States of America. It is obtained from a 82 Sr/ 82g Rb generator [7] . Indeed, 82 Sr has a long half-life (25.55 days). 44 Sc may be used to quantify the kinetics and the dosimetry of antibodies when radioimmunotherapy is performed using the innovative radionuclide 47 Sc [8] . 52 Fe has a half-life of T 1/2 = 8.275 h and has been used in nuclear medicine mainly for imaging in hematology [9] . 55 Co, 76 Br, and 89 Zr have been identified for immuno-PET due to their high abundance of β + decay and their relatively long half-life.
Potential interest at middle term
Radionuclides for therapeutic applications
Two radionuclides have been identified for β − therapy 67 Cu and 47 Sc. They can both be produced in cyclotron using the (p,2p) reaction and then require high proton beam energy (above 30 MeV). Their production cross sections are small (few tens of mb) and the use of highly intense beam is necessary if ones wants to make them available at a reasonable cost. Radiophysical characteristics of these radionuclides fit well to their use in radionuclide therapy.
Last but not least, the α-emitter 211 At also belongs in our priority list. It seems particularly appropriate for alpha-therapy due to its half-life (7.2 hours).
Conclusion
The high energy (up to 70 MeV) and high intensity (350 µA for proton and 35 µA particle for alpha particle) cyclotron AR-RONAX is being built in Nantes (France). It will be devoted to radiochemistry and oncology research and is expected to be in operation in the last quarter of 2008.
A large part of its beam time will be dedicated to the production of radioactive isotopes. In the one hand, PET is most likely to further increase its impact in diagnostic imaging in the future. 211 At). The number of potentially useful radionuclides is relatively limited and the availability of a high-energy, highintensity cyclotron greatly expands this number. Associated with appropriate carriers, these radionuclides will respond to a maximum of unmet clinical needs.
